<DOC>
	<DOC>NCT00239304</DOC>
	<brief_summary>To determine the safety and tolerability of gefitinib in combination with cisplatin and radiation (3D-CRT or IMRT) in patients with locally advanced head and neck cancer.</brief_summary>
	<brief_title>Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirmed head and neck cancer Lymph node negative or positive Metastasis negative Chemo and radiotherapy na√Øve WHO 02 Measurable disease by RECIST Written informed consent Severe alcohol abuse Active ILD Coexisting chronic gastrointestinal disease(s) Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Stage III Head and Neck Cancer</keyword>
	<keyword>Stage IV Head and Neck Cancer</keyword>
</DOC>